This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Wirth, S. M. Articles by Lewis, D. A. PubMed PubMed Citation Articles by Wirth, S. M. Articles by Lewis, D. A. Social Bookmarking                         What's this?

Evaluation of a Clinical Scoring Scale to Direct Early Appropriate Therapy in Heparin-Induced Thrombocytopenia

¹ University of Kentucky Healthcare
² University of Kentucky College of Pharmacy

^* To whom correspondence should be addressed. E-mail: smwirt2{at}email.uky.edu.

	Abstract

Background. Heparin-induced thrombocytopenia (HIT) is a serious adverse effect associated with heparin therapy. Current laboratory confirmation for immune mediated HIT often results in false positives and unnecessary treatment, exposing individuals to possible complications. As a result, clinical evaluation has been recommended in conjunction with laboratory testing. We hypothesize that utilization of a clinical scoring scale, the 4T’s, will result in the initial appropriate therapy for suspected HIT.

Methods. This is a retrospective chart review of 108 patients who underwent ELISA testing for HIT at a university hospital. The 4T’s scale was applied, stratifying individuals into low, intermediate, and high-risk categories. Each risk score was compared to the ELISA results to determine if the 4T’s can predict the diagnosis of HIT and result in appropriate management. ELISA optical density scores as well as incidence of adverse events were also compared among risk categories.

Study Results. Individuals with low risk correlate with a negative ELISA compared to intermediate and high-risk individuals (p = 0.01 and p < 0.01) and also were significantly more likely to predict institution of appropriate therapy (p < 0.01). Median optical density scores were 0.184 (0.046--2.116), 0.226 (0.067--1.887), and 0.476 (0.096--1.309) for low, intermediate, and high 4T scores. Major adverse events include thrombosis and bleeding.

Conclusions. Individuals with low risk were more likely to receive initial, appropriate therapy and were also significantly more likely to have a negative ELISA test result. Individuals with low risk determined by the 4T score therefore may have therapy and serologic testing for HIT withheld.

First published on August 19, 2009
Journal of Oncology Pharmacy Practice 2009, doi:10.1177/1078155209342133


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?